Beta Bionics, Inc.
NASDAQ:BBNXMedical - Equipment & Services
+$0.42 today
- Market cap
- $644.70M
- Beta
- 3.39
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.50
Volume 1.38M
Average 0.99M
BBNX Account Payables
Amounts the company owes suppliers for goods and services received.
Beta Bionics, Inc.NASDAQ: BBNX
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables falls 32.9% from a year ago
Account payables stood at $2.32M at the end of Q1 FY2026, down 32.9% from a year earlier and down 53.6% from the prior quarter. Over 3 fiscal years it compounded at +126.5% a year.
Context
- Account payables amounted to 0.8% of total assets at the end of Q1 FY2026, down 0.3 pp from a year earlier.
- Account payables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -32.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 5M USD
- Year-over-year change
- +75.2%
- 3-year CAGR
- +126.5%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5M | +75.2% |
| FY2024 | 2024-12-31 | 2.85M | +144.6% |
| FY2023 | 2023-12-31 | 1.17M | +171.2% |
| FY2022 | 2022-12-31 | 430K | — |
Account Payables vs competitors
How BBNX compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -32.9% is the lowest of 7, against a peer median of +14.2%.
- Account payables amounts to 0.8% of total assets for BBNX, versus a peer median of 5.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | DKK 154.79B DKK | +448.8% | +8.2% | 26.0% | |
| Jun 2026 | $423.8M USD | -10.2% | +13.1% | 6.6% | |
MMEDMiniMed Group, Inc. Common Stock | Jul 2026 | $251M USD | — | — | 5.3% |
| Jun 2026 | $123.3M USD | +28.3% | +34.5% | 3.9% | |
| Mar 2026 | $59.86M USD | +0.1% | -5.5% | 5.2% | |
| Mar 2026 | $16.14M USD | +220.3% | -6.5% | 2.2% | |
| Mar 2026 | $2.32M USD | -32.9% | +126.5% | 0.8% | |
| Mar 2026 | $481K USD | -5.5% | -41.2% | 0.2% | |
| Peer median (excluding BBNX) | — | +14.2% | +1.4% | 5.2% | |
Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Beta Bionics, Inc.
NASDAQ:BBNX
Intrinsic Alpha fair value
Locked
Current Price
$14.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.